OpenNashEarnings

Medical Devices · NYSE: BDX

Becton Dickinson earnings: results, call transcripts & KPI history

2 quarters · fiscal year ends September · next results expected around 8 Feb 2027

Investor relations ↗SEC filings ↗KPIs as CSV

Latest: Q4 FY2026

BD signed a U.S. government manufacturing partnership with $19 billion of planned investment and Section 232 tariff relief, while launching new vascular and tissue-regeneration products as New BD.

BD finished its transformation into a four-segment MedTech company after spinning off its Biosciences and Diagnostic Solutions business into Waters in February. Growth was led by Advanced Patient Monitoring, PureWick, Advanced Tissue Regeneration, biologic drug delivery and BD Rowa. Interventional grew fastest of the four segments. Connected Care lagged as Alaris infusion pump capital sales fell. BD also won U.S. launch clearance for new vascular and hernia products.

Read the Q4 FY2026 summary →Q4 FY2026 slides (PDF) ↗

Quarters

KPI history

Revenue$5.0B+5.4% y/yQ3 FY26
Q4 FY24: $5.4B (worked out from the annual figure)Q4 24$5.4BQ1 FY25: $5.2BQ1 25$5.2BQ2 FY25: $4.5BQ2 25$4.5BQ3 FY25: $4.7BQ3 25$4.7BQ4 FY25: $8.3B (worked out from the annual figure)Q4 25$8.3BQ1 FY26: $5.3BQ1 26$5.3BQ2 FY26: $4.7BQ2 26$4.7BQ3 FY26: $5.0BQ3 26$5.0B

Fourth quarter worked out from the annual figure.

Data
Q4 FY24$5.4B *
Q1 FY25$5.2B
Q2 FY25$4.5B
Q3 FY25$4.7B
Q4 FY25$8.3B *
Q1 FY26$5.3B
Q2 FY26$4.7B
Q3 FY26$5.0B
Diluted EPS (GAAP)$1.37−31.5% y/yQ3 FY26
Q1 FY25: $1.04Q1 25$1.04Q2 FY25: $1.07Q2 25$1.07Q3 FY25: $2.00Q3 25$2.00Q1 FY26: $1.34Q1 26$1.34Q2 FY26: -$1.11Q2 26-$1.11Q3 FY26: $1.37Q3 26$1.37
Data
Q1 FY25$1.04
Q2 FY25$1.07
Q3 FY25$2.00
Q1 FY26$1.34
Q2 FY26-$1.11
Q3 FY26$1.37

Fourth-quarter EPS appears once the press release is read; filings report it only for the full year.

Operating margin13.3%−2.3 pts y/yQ3 FY26
Q4 FY24: 11.4%Q4 2411.4%Q1 FY25: 8.8%Q1 258.8%Q2 FY25: 8.5%Q2 258.5%Q3 FY25: 15.6%Q3 2515.6%Q4 FY25: 14.1%Q4 2514.1%Q1 FY26: 10.5%Q1 2610.5%Q2 FY26: 2.0%Q2 262.0%Q3 FY26: 13.3%Q3 2613.3%
Data
Q4 FY2411.4%
Q1 FY258.8%
Q2 FY258.5%
Q3 FY2515.6%
Q4 FY2514.1%
Q1 FY2610.5%
Q2 FY262.0%
Q3 FY2613.3%
Free cash flow$549.0M−6.6% y/yQ1 FY26
Q1 FY25: $588.0MQ1 25$588.0MQ1 FY26: $549.0MQ1 26$549.0M
Data
Q1 FY25$588.0M
Q1 FY26$549.0M

Operating cash flow minus capital expenditure, from cash flow statements.

Q4 FY24Q1 FY25Q2 FY25Q3 FY25Q4 FY25Q1 FY26Q2 FY26Q3 FY26
Revenue$5.4Bd$5.2B$4.5B$4.7B$8.3Bd$5.3B$4.7B$5.0B
Operating income$622.0Md$453.0M$383.0M$739.0M$1.2Bd$552.0M$93.0M$663.0M
Operating margin11.4%8.8%8.5%15.6%14.1%10.5%2.0%13.3%
Net income$400.0Md$303.0M$308.0M$574.0M$493.0Md$382.0M-$311.0M$377.0M
Diluted EPS—$1.04$1.07$2.00—$1.34-$1.11$1.37
Operating cash flow—$693.0M———$657.0M——
Capital expenditure$296.0Md$105.0M$114.0Md$164.0Md$377.0Md$108.0M$125.0Md$143.0Md
Free cash flow—$588.0M———$549.0M——
R&D expense$302.0Md$343.0M$232.0M$230.0M$559.0Md$306.0M$249.0M$258.0M

From XBRL data in 10-Q and 10-K filings. d derived: a fourth quarter is the full year minus the first nine months, and cash flows are year-to-date figures differenced.

10-K and 10-Q filings